Comorbidity and Healthcare Expenditure in Women with Osteoporosis Living in the Basque Country (Spain)

Roberto Nuño-Solinis, Carolina Rodríguez-Pereira, Edurne Alonso-Morán, and Juan F. Orueta

1 O+Berri, Basque Institute for Healthcare Innovation, Torre del BEC (Bilbao Exhibition Centre), Ronda de Azkue 1, 48902 Barakaldo, Spain
2 Osakidetza, Basque Health Service, Astrabudua Health Center, Mezo 35, 48950 Erandio, Spain

Correspondence should be addressed to Carolina Rodriguez-Pereira; carodriguezpereira@gmail.com

Received 8 April 2014; Revised 10 July 2014; Accepted 25 July 2014; Published 1 October 2014

Academic Editor: Harri Sievänen

Copyright © 2014 Roberto Nuño-Solinis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. This study aimed to establish the prevalence of multimorbidity in women diagnosed with osteoporosis and to report it by deprivation index. The characteristics of comorbidity in osteoporotic women are compared to the general female chronic population, and the impact on healthcare expenditure of this population group is estimated.

Methods. A cross-sectional analysis that included all Basque Country women aged 45 years and over (N = 579,575) was performed. Sociodemographic, diagnostic, and healthcare cost data were extracted from electronic databases for a one-year period. Chronic conditions were identified from their diagnoses and prescriptions. The existence of two or more chronic diseases out of a list of 47 was defined as multimorbidity. Results. 9.12% of women presented osteoporosis and 85.04% of them were multimorbid. Although multimorbidity in osteoporosis increased with age and deprivation level, prevalence was higher in the better-off groups. Women with osteoporosis had greater risk of having other musculoskeletal disorders but less risk of having diabetes (RR = 0.65) than chronic patients without osteoporosis. People with poorer socioeconomic status had higher healthcare cost. Conclusions. Most women with osteoporosis have multimorbidity. The variety of conditions emphasises the complexity of clinical management in this group and the importance of maintaining a generalist and multidisciplinary approach to their clinical care.

1. Background

Multimorbidity, defined as two or more coexisting chronic conditions within an individual [1], is a growing phenomenon in ageing societies and is especially prevalent in older age groups [2–4]. Multimorbidity makes management of chronic conditions by clinicians more complex; they often lack evidence on the best care strategies to follow with this type of patient. In fact, clinical guidelines rarely address multimorbidity and clinical trials often exclude comorbid and older patients [5, 6]. Individuals manifesting multimorbidity are typically associated with higher degrees of disability, lower quality of life, greater psychological distress and mortality risk [7–9], and increased use of health (and social) care [10, 11] services than if we considered these chronic conditions in isolation or individuals with a single chronic condition. It is of particular relevance for patients, their carers, and healthcare providers, but increasingly a concern for policy makers and societies as a whole [7]. Therefore, it is widely accepted that health systems need to focus their strategies in organising healthcare provision and planning for multimorbid patients and pay attention to the implications on treatment patterns and combinations [12, 13].

Because of its worldwide prevalence, osteoporosis is also considered a serious public health concern. Ageing of populations worldwide will be responsible for a major increase in the incidence of osteoporosis in postmenopausal women [14]. The quality of life of postmenopausal women with osteoporosis is adversely affected if they have bone fractures and pain [13].

Previous studies by this research group have revealed high levels (91%) of coexisting disease among women with
osteoporosis over 65 years old [15]. Furthermore, osteoporosis and bronchiectasis are the only two diseases, out of a list of 52, disproportionally more prevalent among women living in richer areas in the Basque Country [16].

Osteoporosis is among the most prevalent conditions in the multimorbidity literature. The presence of coexisting conditions in women with osteoporosis has been revealed to reduce health-related quality of life, increase the risk of vertebral fractures, and contribute to mortality [17, 18].

The aim of this study was to establish the prevalence of multimorbidity in women with osteoporosis living in the Basque Country, to categorise the number and types of additional chronic conditions recorded, and to report the demographic and socioeconomic characteristics (age and deprivation index). Finally, healthcare expenditure was estimated for this population.

2. Methods

A descriptive study was carried out which included all women aged 45 and above with at least one chronic condition \( N = 397,940 \) who were covered by public health insurance in the Basque Country on 31st August 2011 and who had been covered for at least 6 months in the previous year, regardless of whether or not they had made any contact with or use of the Basque Health Service-Osakidetza. The study compared those women with an osteoporosis diagnosis \( N = 52,844 \) versus those women without a diagnosis of osteoporosis \( n = 345,096 \). The study period was from 1 September 2010 to 31 August 2011. Therefore, we observed almost all of the inhabitants of the Basque Country, by census data in addition to irregular immigrants who have a health identification card and have used the healthcare system during the study period.

Our dataset is derived from the database set up by the population stratification programme (PREST) of Osakidetza. A more detailed description is available by Orueta et al. (2013) [19] and Nuño-Solinis et al. (2012) [20]. In addition, in Osakidetza, diagnoses are coded according to international classification of diseases (ICD-9-MC) [21], while the anatomical, therapeutic, chemical (ATC) [22] coding system is used for drugs prescribed by primary care doctors. With this information, citizens in the Basque Country are classified annually using ACGs (adjusted clinical groups), a case mix system developed at The Johns Hopkins University [23], which enables health problems to be identified from diagnoses and prescriptions, in addition to categorising citizens according to their healthcare needs and cost into a hundred groups.

With the aim of studying multimorbidity and comorbidity of chronic diseases and osteoporosis, we adopted a list of 52 pathologies, defined by consensus among the research team. This task was based on adapting two preexisting lists, published by other authors, the 40 diseases selected by Barnett et al. (2012) [24] and the conditions considered to be chronic in the ACG Technical Reference Guide [23]. A detailed description of this dataset can be found in a previously published article [16].

From the aforementioned list, we omitted four pathologies, “attention deficit disorder,” “intellectual disability,” “anorexia and bulimia” because these diagnoses are very rare in the age group under study, and “prostatic hypertrophy,” because the study includes only women. Therefore, our definitive list was comprised of 47 chronic conditions.

2.1. Variables and Analysis. As a social indicator, the deprivation index of census tract was used [25]. A tract is the smallest geographical unit \( n = 1,200 \) inhabitants which population census data can be broken down; this was created according to population size, geographical, and urban criteria. As the tracts are so small, they tend to be quite homogeneous with respect to the type of dwellings. The deprivation index is an ordinal variable, categorised into five levels, which provides a measure of the socioeconomic characteristics of census tracts and is drawn from the following factors: manual workers, unemployment, temporary employees, and inadequate level of education in the population overall and in young people. The first quintile represents the richest and the fifth quintile the poorest.

We measured health care provision in terms of cost-weighted utilisation of health care. Health care use was estimated for a 12-month period (from 1 September 2010 to 31 August 2011). We consider the cost of the following types of services separately: primary care (including visits to physicians and nurses, laboratory test, and radiology examinations), specialised outpatient care (visits to specialists, rehabilitation, dialysis, radiotherapy, and chemotherapy services), inpatient stays, emergency department attendance, and prescribing. In the case of prescribing, the cost was computed directly from primary care prescriptions recorded in the electronic health records. For other types of use, the number of services for each patient was multiplied by a standardised cost. The costs of hospitalisation and outpatient surgery were calculated in relation to their weight in the corresponding diagnosis related groups (DRGs). Information on some services was not available and these were therefore excluded from the analysis, admission to psychiatric hospitals, home hospitalisation and day care services (except for procedures and services listed above), health care transport, and prostheses and other equipment provided to patients at home.

The prevalence of osteoporosis stratified by age group and deprivation index was obtained; the nonparametric Kruskal-Wallis test was applied to see whether there were differences between these groups. The number of chronic comorbidities for women with osteoporosis was calculated; this was compared against the chronic women without osteoporosis by the nonparametric Wilcoxon Mann-Whitney test. In addition, the average of chronic diseases for women with osteoporosis and without osteoporosis aged >44, stratified by deprivation index, was performed. The 47 risk ratios for the list of chronic conditions with osteoporosis as comorbidity were calculated. Moreover, the average of the observed healthcare costs in women with osteoporosis was obtained.

Statistical calculations were performed using Stata, Data Analysis and Statistical Software, Release 12 (StataCorp, LP, College Station, TX, USA).
3. Results

Out of 579,575 women above 44 years, 52,844 (9.12%) presented osteoporosis. Table 1 shows the prevalence and distribution of women with osteoporosis according to age band and deprivation index. It can be observed that the higher percentage of these is aged 55 to 64 (24.73%) and furthermore the prevalence of this disease increased up to the age of 80. As for the deprivation index we observed that osteoporosis presents more commonly in women with a higher socioeconomic level (24.50%). The prevalence of osteoporosis was higher among rich people. However, no decreasing gradient was observed. After applying the nonparametric Kruskal-Wallis test, statistically significant differences were obtained between the different age bands ($P < 0.001$) and between the different deprivation index groups ($P < 0.001$).

Table 2 shows the number of chronic pathologies for women with and without osteoporosis; the latter subgroup was comprised of 345,096 women. It was observed that only 14.96% of women with osteoporosis only suffer from this chronic disease compared to 36.59% of chronic women over 44 without osteoporosis. It is notable that 1.47% of women with osteoporosis have 10 or more chronic pathologies, compared to 0.35% of women without osteoporosis. The difference in the distribution of the number of chronic pathologies between these two groups was statistically significant ($P < 0.001$). Furthermore, a decreasing gradient was observed in both population subgroups. Therefore, it can be stated that 85.04% of women with osteoporosis and 63.41% of women without osteoporosis over 44 have multimorbidity.

Figure 1 shows the average of the number of chronic pathologies of women over 44 with and without osteoporosis by age and Figure 2 shows the average of the number of chronic pathologies by deprivation index in the same groups. As can be observed, this average increased with age and socioeconomic index and was higher in more depressed areas. Comparing both groups, the chronic women without osteoporosis have higher chronic condition average until 75 years; after this age women with osteoporosis have higher average. However, from socioeconomic levels 2 to 5, women with osteoporosis have greater chronic condition averages.

The association between osteoporosis and other chronic conditions was statistically significant in 38 of them. Table 3 shows the risk ratios between osteoporosis and the other chronic pathologies. The people with osteoporosis have nearly two times more risk of suffering bronchiectasis (1.7) than women without osteoporosis. However, women with osteoporosis have less risk of having diabetes (0.65) than women without osteoporosis.

Regarding cost analysis by deprivation index, we checked that, as socioeconomic level reduces, healthcare costs increase in women with osteoporosis both with one pathology and as the number of these pathologies increases (see Figure 3).

4. Discussion

This population-based study covering the whole female population over 44 years of a large region analysed the prevalence of multimorbidity in this population and indicated that 85.04% of women in this age group with osteoporosis have multimorbidity. These figures are much higher than those found in other studies performed with a Spanish population in which the prevalence of multimorbidity is approximately
Table 2: Distribution of women with osteoporosis and without osteoporosis by the number of comorbidities.

| Number of chronic conditions | Number of women without osteoporosis | Percent of women without osteoporosis | Number of women with osteoporosis | Percent of women with osteoporosis |
|-----------------------------|--------------------------------------|--------------------------------------|----------------------------------|----------------------------------|
| 1                           | 126,284                              | 36.59%                               | 7,904                            | 14.96%                           |
| 2                           | 89,732                               | 26.00%                               | 11,144                           | 21.09%                           |
| 3                           | 56,847                               | 16.47%                               | 10,933                           | 20.69%                           |
| 4                           | 33,424                               | 9.69%                                | 8,465                            | 16.02%                           |
| 5                           | 18,641                               | 5.40%                                | 5,856                            | 11.08%                           |
| 6                           | 9,776                                | 2.83%                                | 2,182                            | 4.13%                            |
| 7                           | 5,190                                | 1.50%                                | 1,264                            | 2.39%                            |
| 8                           | 2,667                                | 0.77%                                | 726                              | 1.37%                            |
| 9                           | 1,321                                | 0.38%                                | 778                              | 1.47%                            |
| 10 or more                  | 1,214                                | 0.35%                                |                                  |                                  |
| Total                       | 345,096                              | 100.00%                              | 52,844                           | 100.00%                          |

Figure 3: Observed average healthcare cost in women with osteoporosis by number of chronic conditions and deprivation index.

As socioeconomic level decreases, the health cost is higher. These results coincide with those found in other studies performed in the Basque Country, where we observe that people with a low socioeconomic level use more health resources [16]; that is, inequality in favour of the poor seems to be within Osakidetza. These data could be accounted for by the fact that people with more financial resources use private healthcare to a greater extent than the least affluent to avoid waiting lists [31, 32]. Perhaps the greater use of private healthcare can also account for the higher prevalence of osteoporosis present at higher socioeconomic levels, not because of the actual presence of more osteoporosis in this population but rather because this diagnosis is made more commonly in private healthcare.

A difference between this study and others found in the literature is that the study is performed using data from a health system with universal cover; this includes virtually the entire Basque Country population which reduces the bias that could occur using a restricted population sample. The database used contains primary care, specialised care, and outpatient hospital care information. This use of different data sources reduces the imprecision that could arise in the calculations [33, 34] and leads to a better description of health problems [35].

4.1. Limitations of the Study. Given that the administrative databases only contain information on those patients who have requested healthcare, the prevalence obtained only reflects known cases. Those cases, where professionals or patients are unaware, have been excluded; and this is commonplace in the case of osteoporosis. Another limitation is the fact that there is no access to information from private health sector resources. Therefore, there are no data on monitoring of the disease in this sector. Finally, since we use a socioeconomic index collected through area of residence, our study has the limitations of ecological studies.

4.2. Practical Implications. Because osteoporosis usually presents together with other chronic diseases, it is important...
Table 3: Risk ratios for the 47 chronic conditions with osteoporosis as comorbidity.

| Condition                                                                 | Risk ratio | Lower bound | Upper bound |
|---------------------------------------------------------------------------|------------|-------------|-------------|
| Hypertension                                                              | 0.81       | 0.80        | 0.82        |
| Asthma (currently treated)                                                | 1.18       | 1.14        | 1.22        |
| Ischemic heart disease                                                    | 1.10       | 1.06        | 1.15        |
| Diabetes mellitus                                                         | 0.65       | 0.64        | 0.67        |
| Hypothyroidism                                                            | 0.93       | 0.91        | 0.95        |
| Rheumatoid arthritis and autoimmune and connective tissue diseases       | 1.45       | 1.40        | 1.50        |
| Deafness and hearing loss                                                 | 1.13       | 1.08        | 1.17        |
| Emphysema, chronic bronchitis, and COPD                                   | 1.31       | 1.26        | 1.35        |
| Irritable bowel syndrome                                                  | 1.35       | 1.26        | 1.44        |
| Malignancies                                                              | 1.07       | 1.04        | 1.10        |
| Cerebrovascular disease                                                   | 1.22       | 1.18        | 1.26        |
| Chronic kidney disease                                                    | 1.07       | 1.02        | 1.12        |
| Diverticular disease of intestine                                          | 1.55       | 1.49        | 1.61        |
| Peripheral vascular disease                                               | 1.17       | 1.04        | 1.31        |
| Heart failure                                                             | 1.19       | 1.14        | 1.25        |
| Glaucoma                                                                  | 1.06       | 1.03        | 1.09        |
| Dementia                                                                  | 1.01       | 0.97        | 1.04        |
| Schizophrenia, affective psychosis, or bipolar disorder                   | 0.62       | 0.57        | 0.68        |
| Inflammatory bowel disease                                                | 1.13       | 1.03        | 1.24        |
| Parkinson's disease                                                       | 1.22       | 1.15        | 1.29        |
| Multiple sclerosis                                                        | 0.84       | 0.69        | 1.03        |
| Chronic liver or pancreatic disease                                       | 1.11       | 1.05        | 1.19        |
| Paralysis or muscular dystrophy                                           | 1.18       | 1.10        | 1.27        |
| Chronic heart disease and others                                          | 1.21       | 1.17        | 1.26        |
| VIH                                                                       | 0.37       | 0.24        | 0.56        |
| Hematologic chronic disorders                                             | 1.04       | 0.93        | 1.16        |
| Chromosomal anomalies or inherited metabolic disorders                    | 0.98       | 0.92        | 1.05        |
| Transplant status                                                         | 1.16       | 0.97        | 1.41        |
| Disorders of the immune system                                            | 1.46       | 1.36        | 1.57        |
| Degenerative joint disease                                                | 1.40       | 1.38        | 1.43        |
| Peripheral neuropathy and neuritis                                        | 0.86       | 0.83        | 0.89        |
| Gout                                                                      | 0.88       | 0.80        | 0.97        |
| Treated constipation                                                       | 1.60       | 1.51        | 1.69        |
| Psoriasis or eczema                                                        | 1.08       | 0.96        | 1.21        |
| Migraine                                                                  | 0.82       | 0.74        | 0.91        |
| Alcohol problems                                                          | 0.66       | 0.56        | 0.79        |
| Bronchiectasis                                                            | 1.70       | 1.59        | 1.83        |
| Depression                                                                | 1.12       | 1.09        | 1.14        |
| Epilepsy (currently treated)                                              | 0.85       | 0.77        | 0.95        |
| Atrial fibrillation                                                       | 1.08       | 1.05        | 1.12        |
| Viral hepatitis                                                            | 1.03       | 0.94        | 1.12        |
| Low back pain                                                             | 1.25       | 1.22        | 1.28        |
| Chronic sinusitis                                                         | 1.10       | 0.99        | 1.23        |
| Abuse substances                                                          | 0.83       | 0.59        | 1.16        |
| Treated dyspepsia                                                         | 1.42       | 1.39        | 1.45        |
| Anxiety and other neurotic, stress related, and somatoform disorders      | 0.86       | 0.84        | 0.87        |
| Blindness and low vision                                                  | 1.07       | 1.03        | 1.12        |
for clinicians to consider the interactions that other multimorbid pathologies and their treatments can have on this. Its onset, frequently insidious, may mean that treatment is focused on another more serious chronic pathology, leaving osteoporosis and its treatment to one side [36]. However, this disease is a significant health problem because of the serious consequences of bone fractures [18]. With the ageing of the population, it is expected that the number of fractures will increase considerably over the next few years along with healthcare costs [14]. Suitable treatment of multimorbidity in people who suffer from osteoporosis, which slows down course and prevents fractures, is a challenge for health systems.

5. Conclusions

A high percentage of women with an osteoporosis diagnosis presents at least one other chronic disease and the prevalence of multimorbidity is much higher in women with disadvantaged socioeconomic levels. The comorbidity present in osteoporosis patients should be considered for both correct clinical management and setting up suitable treatments and when drawing up health policies.

Abbreviations

ICD-9-MC: International classification of diseases
ATC: Anatomical therapeutic chemical classification system
ACGs: Adjusted clinical groups
DRGs: Diagnosis related groups
ADGs: Aggregated diagnosis groups.

Conflict of Interests

The authors declare that they have no competing interests.

Acknowledgments

The authors would like to thank MEDEA project team of the Basque Country for calculating and providing the deprivation index and especially Montse Calvo for the work of geocoding data.

References

[1] J. M. Valderas, B. Starfield, B. Sibbald, C. Salisbury, and M. Roland, “Defining comorbidity: Implications for understanding health and health services,” Annals of Family Medicine, vol. 7, no. 4, pp. 357–363, 2009.
[2] E. Loza, J. A. Jover, L. Rodriguez, and L. Carmona, “Multimorbidity: prevalence, effect on quality of life and daily functioning, and variation of this effect when one condition is a rheumatic disease,” Seminars in Arthritis and Rheumatism, vol. 38, no. 4, pp. 312–319, 2009.
[3] M. Fortin, M. Stewart, M. Poitras, J. Almirall, and H. Maddocks, “A systematic review of prevalence studies on multimorbidity: toward a more uniform methodology,” Annals of Family Medicine, vol. 10, no. 2, pp. 142–151, 2012.
[4] M. E. Salive, “Multimorbidity in older adults,” Epidemiologic Reviews, vol. 35, no. 1, pp. 75–83, 2013.
[5] L. D. Hughes, M. E. T. McMurdo, and B. Guthrie, “Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidity,” Age and Ageing, vol. 42, no. 1, pp. 62–69, 2013.
[6] B. Guthrie, K. Payne, P. Alderson, M. E. T. McMurdo, and S. W. Mercer, “Adapting clinical guidelines to take account of multimorbidity,” British Medical Journal, vol. 345, no. 7878, Article ID e6341, 2012.
[7] I. Kirchberger, C. Meisinger, M. Heier et al., “Patterns of multimorbidity in the aged population. results from the KORA-Age study,” PLoS ONE, vol. 7, no. 1, Article ID e30556, 2012.
[8] M. Fortin, H. Soubhi, C. Hudon, E. A. Bayliss, and M. van den Akker, “Multimorbidity’s many challenges,” The British Medical Journal, vol. 334, no. 7602, pp. 1016–1017, 2007.
[9] C. Vogeli, A. E. Shields, T. A. Lee et al., “Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs,” Journal of General Internal Medicine, vol. 22, no. 3, pp. 391–395, 2007.
[10] J. F. Orueta, E. Alonso-Morán, R. Nuño-Solínis, A. Alday-Jurado, E. Gutiérrez-Fraile, and A. García-Alvarez, “Prevalence and costs of chronicity and multimorbidity in the population covered by the Basque public telecare service,” Anales del servicio sanitario de Navarra, vol. 36, no. 3, pp. 429–440, 2013.
[11] R. Gijsen, N. Hoeymans, F. G. Schellevis, D. Ruwaard, W. A. Satariano, and G. A. M. van den Bos, ”Causes and consequences of comorbidity: a review,” Journal of Clinical Epidemiology, vol. 54, no. 7, pp. 661–674, 2001.
[12] N. E. Schoenberg, H. Kim, W. Edwards, and S. T. Fleming, “Burden of common multiple-morbidity constellations on out-of-pocket medical expenditures among older adults,” The Gerontologist, vol. 47, no. 4, pp. 423–437, 2007.
[13] J. L. Wolff, B. Starfield, and G. Anderson, “Prevalence, expenditures, and complications of multiple chronic conditions in the elderly,” Archives of Internal Medicine, vol. 162, no. 20, pp. 2269–2276, 2002.
[14] P. Geusens and G. Dinant, “Integrating a gender dimension into osteoporosis and fracture risk research,” Gender Medicine, vol. 4, supplement 2, pp. S147–S161, 2007.
[15] J. F. Orueta, R. Nuño-Solínis, A. García-Alvarez, and E. Alonso-Morán, “Prevalence of multimorbidity according to the deprivation level among the elderly in the Basque Country,” BMC Public Health, vol. 13, article 918, 2013.
[16] J. F. Orueta, A. García-Alvarez, E. Alonso-Morán, L. Vallejo-Torres, and R. Nuño-Solínis, “Socioeconomic variation in the burden of chronic conditions and health care provision—analyzing administrative individual level data from the Basque Country, Spain,” BMC Public Health, vol. 13, article 870, 2013.
[17] J. A. Kanis, O. Johnell, A. Oden, B. Jonsson, C. de Laet, and A. Dawson, ”Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis,” Bone, vol. 27, no. 5, pp. 585–590, 2000.
[18] A. D. Woolf and B. Pfleger, “Burden of major musculoskeletal conditions,” Bulletin of the World Health Organization, vol. 81, no. 9, pp. 646–656, 2003.
[19] J. F. Orueta, M. Mateos Del Pino, I. Barrio Beraza, R. Nuño Solínis, M. Cuadrado Zubizarreta, and C. Sola Sarabia, “Stratification of the population in the Basque Country: results in the first year of implementation,” Atencion Primaria, vol. 45, no. 1, pp. 54–60, 2013.
[20] R. Nuño-Solinis, J. F. Orueta, and M. Mateos, “An answer to chronicity in the Basque Country: primary care-based population health management,” The Journal of Ambulatory Care Management, vol. 35, no. 3, pp. 167–173, 2012.

[21] Spanish Institute of Health Information, “Spanish version (eCIE9MC) of the electronic International Classification of Diseases,” Ninth Revision, Clinical Modification (ICD-9-CM), 2012.

[22] The WHO Collaborating Centre for Drug Statistics Methodology, International Language for Drug Utilization Research ATC/DDD, 2012.

[23] Johns Hopkins Bloomberg School of Public Health, The Johns Hopkins ACG Case-Mix System Technical Reference Guide Manual Version 9.0, 2009.

[24] K. Barnett, S. W. Mercer, M. Norbury, G. Watt, S. Wyke, and B. Guthrie, “Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study,” The Lancet, vol. 380, no. 9836, pp. 37–43, 2012.

[25] M. F. Domínguez-Berjón, C. Borrell, G. Cano-Serral et al., “Constructing a deprivation index based on census data in large Spanish cities [the MEDEA project],” Gaceta Sanitaria, vol. 22, no. 3, pp. 179–187, 2008.

[26] Grupo de trabajo de la SEIOMM, “Osteoporosis posmenopáusica. Guía de práctica clínica. Sociedad española de investigaciones óseas y metabolismo mineral,” Revista Clínica Española, vol. 203, no. 10, pp. 496–506, 2003.

[27] J. A. A. Dalstra, A. E. Kunst, C. Borell et al., “Socioeconomic differences in the prevalence of common chronic diseases: an overview of eight European countries,” International Journal of Epidemiology, vol. 34, no. 2, pp. 316–326, 2005.

[28] I. Schäfer, H. Hansen, G. Schön et al., “The influence of age, gender and socio-economic status on multimorbidity patterns in primary care. First results from the multicare cohort study,” BMC Health Services Research, vol. 12, article 89, 2012.

[29] C. B. Agborsangaya, D. Lau, M. Lahtinen, T. Cooke, and J. A. Johnson, “Multimorbidity prevalence and patterns across socioeconomic determinants: a cross-sectional survey,” BMC Public Health, vol. 12, article 201, 2012.

[30] C. Borrell, E. Fernandez, A. Schiaffino et al., “Social class inequalities in the use of and access to health services in Catalonia, Spain: what is the influence of supplemental private health insurance?” International Journal for Quality in Health Care, vol. 13, no. 2, pp. 117–125, 2001.

[31] C. S. Tsoi, J. Y. Chow, K. S. Choi et al., “Medical characteristics of the oldest old: retrospective chart review of patients aged 85+ in an academic primary care centre,” BMC Research Notes, vol. 7, article 340, 2014.

[32] M. L. González Álvarez and A. C. Barranquero, “Inequalities in health care utilization in Spain due to double insurance coverage: an Oaxaca-Ransom decomposition,” Social Science and Medicine, vol. 69, no. 5, pp. 793–801, 2009.

[33] J. Aubé-Maurice, L. Rochette, and C. Blais, “Divergent associations between incident hypertension and deprivation based on different sources of case identification,” Chronic Diseases and Injuries in Canada, vol. 32, no. 3, pp. 121–130, 2012.

[34] H. Van Den Bussche, I. Schäfer, B. Wiese et al., “A comparative study demonstrated that prevalence figures on multimorbidity require cautious interpretation when drawn from a single database,” Journal of Clinical Epidemiology, vol. 66, no. 2, pp. 209–217, 2013.

[35] J. F. Orueta, R. Nuño-Solinis, M. Mateos, I. Vergara, G. Grandes, and S. Esnaola, “Monitoring the prevalence of chronic conditions: which data should we use?” BMC Health Services Research, vol. 12, no. 1, article 365, 2012.

[36] C. David, C. B. Confavreux, N. Mehsen, J. Paccou, A. Leboime, and E. Legrand, “Severity of osteoporosis: what is the impact of co-morbidities?” Joint Bone Spine: Revue du Rhumatisme, vol. 77, supplement 2, pp. S103–S106, 2010.